Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.

Journal of clinical pharmacology - 1 Mar 2008

Kalliokoski Annikka, Neuvonen Mikko, Neuvonen Pertti J, Niemi Mikko

Abstract excerpt

Thirty-two healthy volunteers with different SLCO1B1 genotypes ingested a 0.5-mg dose of repaglinide and 60-mg dose of nateglinide with a washout period of 1 week. Participants with SLCO1B1 c.521CC genotype (n = 4) had a 59% (P = 0.001) or 72% (P < 0.001) greater mean area under the plasma repaglinide concentration-time curve (AUC(0-infinity)) than participants with c.521TC (n = 12) or c.521TT (n = 16) genotypes....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Cyclohexanes
Share to Cytochrome P-450 CYP2C8

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Half-Life

Share to Liver-Specific Organic Anion Transporter 1

Share to Metabolic Clearance Rate

Share to Organic Anion Transporters

Share to Piperidines

Source

Identifiers

PMID: 18187595
DOI: 10.1177/0091270007311569

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.PMID 18187595Read ↗

The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.Semantic proximity Read ↗

Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

Effect of pitavastatin in different SLCO1B1 backgrounds on repaglinide pharmacokinetics and pharmacodynamics in healthy Chinese males.Semantic proximity Read ↗

Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.Semantic proximity Read ↗

Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.Semantic proximity Read ↗

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.Semantic proximity Read ↗

The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers.Semantic proximity Read ↗

Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide.Semantic proximity Read ↗

Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.Semantic proximity Read ↗

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers.Semantic proximity Read ↗

SLCO1B1 polymorphism and oral antidiabetic drugs.Semantic proximity Read ↗

CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.